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Abstract: MET is located on chromosome 7q31 and is a proto-oncogene that encodes for hepa-
tocyte growth factor (HGF) receptor, a member of the receptor tyrosine kinase (RTK)  family. 
HGF, also known as scatter factor (SF), is the only known ligand for MET. MET is a master 
regulator of cell growth and division (mitogenesis), mobility (motogenesis), and differentiation 
(morphogenesis); it plays an important role in normal development and tissue regeneration. The 
HGF-MET axis is frequently dysregulated in cancer by MET gene amplification, translocation, 
and mutation, or by MET or HGF protein overexpression. MET dysregulation is associated with 
an increased propensity for metastatic disease and poor overall prognosis across multiple tumor 
types. Targeting the dysregulated HGF-MET pathway is an area of active research; a number 
of monoclonal antibodies to HGF and MET, as well as small molecule inhibitors of MET, are 
under development. This review summarizes the key biological features of the HGF-MET axis, 
its dysregulation in cancer, and the therapeutic agents targeting the HGF-MET axis, which are 
in development.
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Hepatocyte growth factor (HGF)-MET pathway  
in normal development and tumorigenesis
Nearly 30 years ago, HGF was identified as a modulator of hepatocyte proliferation 
and regeneration by three independent groups of investigators.1–3 HGF is a heterodimer 
with a larger α subunit and smaller β subunit with homology to tissue plasminogen.4 
HGF is secreted by cells of mesenchymal origin and binds to the MET receptor on 
epithelial and endothelial cells. Scatter factor (SF), so named due to its ability to scatter 
mammary epithelial cells in culture, was characterized by complementary deoxyri-
bonucleic acid (cDNA) cloning in 1990; SF was found to be identical to HGF, with 
indistinguishable ligand activity for the MET receptor.5 HGF is secreted as a precursor 
polypeptide bound to heparin proteoglycans in the extracellular matrix. The inactive 
HGF polypeptide is cleaved by a serine protease at sites of tissue injury and by tumor 
cells/matrix into active HGF. The only known ligand for the MET receptor is HGF, 
which upon binding to MET activates a downstream cascade, leading to cell survival, 
division, and motility.6
Activated MET kinase undergoes autophosphorylation on tyrosine residues 
(Tyr1349 and Tyr1356) in the docking domain, leading to recruitment and transduction 
of downstream effectors. Activated MET phosphorylates and binds to growth factor 
receptor-bound protein 2 (GRB2) and GRB2-associated binding protein 1 (GAB1), 
acting as a scaffold and promoting MET interactions with proteins involved in the 
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Figure 1 HGF-MeT signaling pathway.
Abbreviations: HGF, hepatocyte growth factor; eRK, extracellular signal-regulated kinase; STAT, signal transducer and activator of transcription factor; GRB2, growth 
factor receptor-bound protein 2; GAB1, GRB2-associated binding protein 1; PLC, phospholipase C; Pi3K, phosphoinositol 3-kinase; Akt, protein kinase B; mTOR, mammalian 
target of rapamycin.
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phosphoinositol 3-kinase (PI3K)-protein kinase B (Akt) 
pathway, the signal transducer and activator of transcription 
factor (STAT) pathway, the mitogen-activated protein kinase 
(MAPK) pathway, and the nuclear factor kappa-light-chain-
enhancer of activated B cells (NFkB) pathway.7 All of these 
pathways form an integral part of the MET-dependent cell 
growth, survival, and migration-signaling cascade. During 
embryogenesis, normal expression and function of HGF, 
MET, and GAB1 are essential for growth and development 
of hepatocytes,8 placental trophoblasts, and myoblasts.9 
After birth, activation of the HGF-MET pathway appears 
to be involved in epithelial-mesenchymal transition,10 
hepatic, renal, and other organ regeneration after injury, and 
wound healing. Figure 1 illustrates the HGF-MET signaling 
pathway.
In a subset of spontaneously transformed NIH-3T3 mouse 
fibroblasts, amplification and subsequent overexpression of 
the mouse MET gene was identified. This amplification was 
not seen in nontransformed NIH-3T3 cells and provided the 
initial proof of concept that the MET oncogene could act as 
a transforming factor.11 Subsequently, MET ribonucleic acid 
(RNA) and protein overexpression was observed in multiple 
epithelial and mesenchymal tumor cell lines, including 
breast, thyroid, liver, and kidney cancers.12 Transgenic mice 
with forced overexpression of HGF were noted to develop 
multiple epithelial and mesenchymal tumors. This diverse 
tumorigenesis was associated with MET phosphorylation and 
autocrine activation. Tumors arising in the tissues of these 
transgenic mice exhibited morphologic and developmental 
abnormalities, establishing the role of the HGF-MET path-
way in tumorigenesis.13
HGF and MET dysregulation  
in cancer
In human malignancies, the HGF-MET axis is dysregulated 
by a number of mechanisms, providing tumor cells with 
the ability to proliferate and disseminate. The MET gene 
is activated by point mutations in small-cell lung cancer 
(SCLC)14 and renal papillary carcinomas.15 MET protein is 
overexpressed in melanoma and musculoskeletal tumors.16 
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Fusion of MET with translocated promoter region (TPR) in 
gastric carcinoma leads to MET overexpression.17–19 Aber-
rant HGF expression leading to autocrine activation of MET 
occurs in nearly half of acute myeloid leukemia cell lines, 
and depletion of HGF or MET leads to inhibition of growth 
and apoptosis.20 Transgenic mice overexpressing HGF have 
increased MET expression in tumor cells, providing them 
with a selective growth advantage; overexpression of HGF in 
tissues is associated with increased incidence of epithelial and 
mesenchymal tumors.13 In an elegant study, Lorenzato et al 
noted that activating somatic MET mutations were infrequent 
in primary tumors but commonly present at metastatic sites, 
suggesting that MET mutations are associated with progres-
sion rather than initiation of tumorigenesis.21 In colorectal 
tumors, MET amplification is associated with advanced 
stages and development of hepatic metastatic disease; gene 
amplification was observed in 2% (3/177) of localized pri-
mary cancers, 9% (6/70) of cancers with distant metastases 
(P,0.02), and 18% (25/147) of liver metastases (P,0.01).22 
Thus, alterations in MET and/or HGF are frequently observed 
in a wide range of cancers, and their presence appears to 
confer an increased propensity for a more aggressive clinical 
behavior manifested by invasion and metastasis.
Overexpression and upregulation of the HGF-MET path-
way has been shown to be an important escape mechanism 
for tumor cells to develop resistance to inhibition of the 
epidermal growth factor receptor (EGFR), RAS-RAF-MEK, 
and Akt–mTOR (mammalian target of rapamycin) pathways. 
In a subset (22%) of non-small-cell lung cancers (NSCLC) 
with activating mutations of the EGFR gene, MET amplifi-
cation is associated with gefitinib resistance by promoting 
human epidermal growth factor receptor (HER)-3-mediated 
activation of PI3K.23 Overexpression of HGF followed by 
MET phosphorylation in NSCLCs with EGFR-activating 
mutations reactivates the PI3K-Akt signaling pathway and 
leads to gefitinib resistance.24 Similarly, resistance to RAS 
inhibitors is mediated by upregulation and secretion of 
HGF by the tumor microenvironment.25 MET activation was 
noted to mediate resistance to HER2 inhibition by lapatinib 
in HER2-amplified gastric cancer cells.26 In esophageal 
squamous cell carcinoma, secretion of HGF by fibroblasts 
is associated with a highly invasive phenotype and early 
disease progression.27 MET amplification is associated with a 
highly aggressive phenotype in a subset of gastro-esophageal 
adenocarcinomas.28 TP53 mutations or p53 deficiency is 
associated with MET dysregulation and promotes tumor 
cell mobility and invasion.29 Alterations in the HGF-MET 
axis can lead to development of resistance to inhibition 
of a number of different pathways; combining HGF/MET 
inhibition with targeted EGFR, MEK, or PI3K inhibitors 
would appear to represent a rational approach to treating 
these resistant tumors.
Targeting the HGF-MET axis
Currently, a number of strategies targeting the HGF-MET 
pathway are in development. These approaches include the 
use of small molecule MET tyrosine kinase inhibitors (TKI), 
anti-HGF neutralizing antibodies, and anti-MET neutraliz-
ing antibodies. Each of these approaches will be reviewed 
below. The molecular sites of action for agents targeting the 
HGF-MET pathway are shown in Figure 2. Table 1 sum-
marizes the target receptors, half-life, and characteristics 
of HGF-MET inhibitors. The development of a number 
of these agents has advanced to evaluation for efficacy in 
Phase II and Phase III clinical trials (Table 2). A timeline of 
significant pathways involving the HGF-MET axis and clini-
cal development of agents targeting the HGF-MET pathway 
is shown in Figure 3.
Adenosine triphosphate (ATP)-
competitive MET kinase inhibitors
Foretinib
Foretinib was developed as a small molecular inhibitor 
of MET and vascular endothelial growth factor (VEGF) 
receptor 2 (VEGFR-2/kinase insert domain receptor 
[KDR]) with additional activity against RON, KIT, fms-
related tyrosine kinase (FLT)-1, FLT-3, platelet-derived 
growth factor receptor (PDGFR)-α, PDGFR-β, fibroblast 
growth factor receptor (FGFR), EGFR, and tyrosine kinase 
with immunoglobulin-like and EGF-like domains (TIE)-2. 
Foretinib inhibits MET at a half maximal inhibitory 
concentration (IC
50
) of 0.4 nmol/L; subsequently, it also 
inhibits HGF-mediated MET phosphorylation, migration, 
and invasion of MET-amplified human gastric cancer cell 
lines. In a mouse model with lung metastases, oral foretinib 
produced a significant dose-dependent reduction in both 
size and number of lung metastases, which led to its further 
development.30
In the initial Phase I trial of foretinib in patients with 
metastatic or unresectable solid tumors, 40 patients were 
enrolled in eight dose cohorts. All patients received foretinib 
for 5 days orally every 14 days. The maximum tolerated 
dose (MTD) was 3.6 mg/kg and dose limiting toxicities 
included aspartate aminotransferase and lipase elevations. 
Responses were seen in two patients with papillary renal cell 
carcinoma and one patient with medullary thyroid carcinoma. 
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Table 1 Summary of MeT-targeted agents, target receptors, maximal tolerated dose, and half-life for HGF and MeT inhibitors
Agent Company Target MTD Half-life References
Foretinib (XL-880) GlaxoSmithKline MeT, RON, KiT, FLT-1, FLT-3, PDGFR-α,  
PDGFR-β, FGFR, eGFR, Tie-2
3.6 mg/kg 40 hours 31
Cabozantinib (XL-184) exelixis MeT, ReT, Tie-2, veGFR1-3, KiT, FLT-3 175 mg daily 80–90 hours 58
Crizotinib Pfizer MeT, ALK 250 mg twice daily 42 hours
Tivantinib (ARQ-197) ArQule MeT
Cytotoxic activity
360 mg twice per day dose  
(crystalline formulation)
300 mg twice per day  
(amorphous formulation)
3.2–6.1 hours 48–50
Rilotumumab (AMG102) Amgen Human HGF Not reached
Max dose, 20 mg/kg
14.5–22 days 73
Ficlatuzumab (Av-299) Aveo Human HGF Not reached
Max dose, 20 mg/kg
15 days 79
Onartuzumab (MetMab) Genentech Human MeT Not reached 11 days
Abbreviations: MTD, maximum tolerated dose; HGF, hepatocyte growth factor; FLT, fms-related tyrosine kinase; PDGFR, platelet-derived growth factor receptor; FGFR, 
fibroblast growth factor; EGFR, epidermal growth factor receptor; TIE-2, tyrosine kinase with immunoglobulin-like and EGF-like domains; VEGFR, vascular endothelial growth 
factor receptor; ALK, anaplastic lymphoma kinase.
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Anti-HGF antibodies
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Figure 2 HGF-MeT inhibitors and potential sites of action.
Abbreviations: HGF, hepatocyte growth factor; ATP, adenosine triphosphate; PSi, plexins-semaphorins-integrins; iPT, immunoglobulin-plexin-transcription.
The  recommended Phase II dose (RP2D) of foretinib was 
determined to be 240 mg daily for 5 days every 14 days.31 The 
half-life for foretinib was determined to be approximately 
40 hours, and no pharmacokinetic differences were observed 
based on age, sex, or body weight.31
In a Phase II study of foretinib in patients with papillary 
renal cell carcinoma, 74 patients were enrolled into two 
cohorts comparing daily to intermittent foretinib. A total of 
37 patients in cohort A received 240 mg foretinib on days 
1–5 every 14 days, while 37 patients in cohort B received 
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80 mg daily foretinib. The overall response rate was 13.5% 
and median progression-free survival was 9.3 months. Five 
of ten patients with a germline MET mutation responded to 
foretinib, while five of 57 patients without germline MET 
mutation responded to foretinib. The most common side 
effects of this agent were fatigue, hypertension, and gastro-
intestinal (GI) toxicity.32,33 This study is unique as the authors 
clearly stratified patients based on germline or acquired MET 
mutations, and they noted that germline MET mutations 
were a stronger predictive marker of response to foretinib 
compared to acquired MET mutations.31,32
Seventy-four patients were enrolled in a Phase II study of 
foretinib in patients with metastatic gastric adenocarcinoma. 
Stable disease was seen in ten of 49 patients on intermit-
tent dosing (240 mg/day, for 5 days, every 2 weeks) and in 
five of 25 patients on continuous dosing daily (80 mg/day). 
Median duration of stable disease was 3.2 months, and the 
study failed to meet its primary endpoint of an objective 
response rate (ORR) .25%. Of 67 patients with tumor 
samples, three had MET amplification, one of whom had 
disease stabilization.34
PHA-665752
PHA-665752 is an ATP-competitive small-molecule inhibi-
tor of the MET kinase with additional activity against RON 
and VEGF2. In gastric carcinoma mouse-xenograft models, 
PHA-665752 inhibited MET phosphorylation and tumor 
growth.35 Treatment with PHA-665752 induced apoptosis in 
five of five gastric cancer cell lines with MET amplification 
but none of twelve cell lines without MET amplification.36 
The addition of PHA-665752 to gefitinib, an EGFR TKI, 
reversed acquired resistance to gefitinib in lung cancer cell 
lines with MET amplification.23
BAY-853474
BAY-853474 is a selective, potent, oral small-molecule 
inhibitor of the MET kinase. BAY-853474 inhibits MET 
autophosphorylation in vitro and inhibits proliferation and 
growth of MET-dependent tumor xenograft models in vivo.37 
BAY-853474 use was associated with reduced tumor bur-
den in glioblastoma, NSCLC, and gastric cancer xenograft 
models. The inhibition of MET phosphorylation was dose-
dependent, and soluble plasma biomarkers HGF, VEGF, 
interleukin-8, and MET-ectodomain predicted response to 
treatment.38
MK-2461
MK-2461 is an inhibitor of MET with additional activity 
against RON, FLT-1, FGFR, PDGFR, and other receptor 
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tyrosine kinases. In MET-amplified human GTL16 gastric 
cancer cell lines and a murine xenograft model of MET-
dependent gastric cancer, oral MK-2461 inhibited MET sig-
naling and cell growth.39 Genomic amplification of MET and 
constitutive activation of MET, FGFR2, or PDGFR2 were 
noted to be predictive of response to MK-2461.39
AMG-458
AMG-458 is a potent inhibitor of the MET, VEGFR-2, and 
insulin-like growth factor 1 receptor signaling pathways.40 
It significantly inhibited tumor growth in the NIH-3T3 cells 
transfected with TPR-MET, leading to constitutive activa-
tion of MET and U-87 MG human glioblastoma xenograft 
models.41 There is currently no clinical trial information 
available for AMG-458.
PF-04217903
PF-04217903 showed excellent in vitro activity against 
the MET-amplified human GTL16 gastric carcinoma and 
H1993 NSCLC cell lines. PF-04217903 partially inhibited 
proliferation in U-87 MG human glioblastoma cells and 
two colon cancer cell lines (SW620, HT29). PF-04217903 
inhibited MET phosphorylation and tumor proliferation in 
both a GTL16 xenograft athymic mouse model with MET 
amplification and in a U-87 MG human glioblastoma xeno-
graft model with an activated HGF-MET autocrine loop.42,43 
A Phase I study of PF-04217903 in advanced cancer was 
terminated by Pfizer in early 2012.
Non-ATP-competitive MET  
kinase inhibitors
Tivantinib
Tivantinib (ARQ 197) is currently undergoing Phase II 
clinical development based upon preclinical cytotoxic 
activity and ATP non-competitive inhibition of MET with a 
minimal IC
50
 of 0.1 µM44 by in vitro assay of recombinant 
kinase protein. Tivantinib binds to a hydrophobic cleft in the 
kinase domain, stabilizing the inactive conformation and 
inhibiting MET autophosphorylation.45 Tivantinib is orally 
Figure 3 A timeline of important discoveries related to the HGF-MeT pathway. Black represents basic science discoveries and red represents clinical/translational discoveries.
Note: Adapted by permission from Macmillan Publishers Ltd: Nature Reviews Cancer. Gherardi e, Birchmeier w, Birchmeier C, vande woude G. Targeting MeT in cancer: 
rationale and progress. Nat Rev Cancer. 2012;12(2): 89–103.101 Copyright © 2012.
Abbreviations: HGF, hepatocyte growth factor; SF, scatter factor; GRB2, growth factor receptor-bound protein 2; GAB1, GRB2-associated binding protein 1; RCC, renal 
cell carcinoma; DNA, deoxyribonucleic acid; FDA, Food and Drug Administration.
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bioavailable, and it is metabolized by the liver cytochrome 
P450 (CYP) CYP2C19, and to a lesser extent by CYP3A4. 
 Polymorphisms in CYP2C19 (CYP2C19*2 and CYP2C19*3) 
have been identified that are associated with decreased metab-
olism of tivantinib, resulting in significantly increased drug 
exposure.46 These polymorphisms are most commonly seen 
in Asians (35% allele frequency), but also occur in African-
Americans (17%) and Caucasians (15%).47
In vitro, tivantinib induced caspase-dependent apoptosis 
in MET-expressing human cancer cell lines, including the 
HT29 (colon adenocarcinoma), MKN-45 (gastric cancer), 
and MDA-MB-231 (breast cancer) cell lines; this small 
molecule demonstrated antitumor activity in a wide range 
of human cancer xenograft models.48
The clinical pharmacology and safety profile of tivan-
tinib have been investigated in several Phase I studies.48–50 
The main dose-limiting toxicities have been leukopenia, 
neutropenia, thrombocytopenia, vomiting, and dehydration. 
At a dose of 400 mg daily, febrile neutropenia was 
observed in two subjects, one of whom also experienced 
grade 3 mucositis, palmar-plantar erythrodysesthesia, and 
hypokalemia.50 All toxicities were reversible upon discon-
tinuation of tivantinib. Drug treatment was associated with 
a decrease in phosphorylated MET, significant decreases in 
total MET and phosphorylated focal adhesion kinase, and 
a significant increase in the level of apoptosis, as measured 
by a terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) assay.50 The RP2D for tivantinib was 
established as 300 mg twice daily of the amorphous for-
mulation, which is equivalent to 360 mg twice daily of the 
crystalline formulation.
In a Phase II study, 47 patients with advanced micro-
phthalmia transcription factor (MITF)-associated tumors 
(MiT) were treated with 360 mg twice daily tivantinib.51 
The study concluded that tivantinib was safe and tolerable in 
patients with MiT tumors, but antitumor activity was relatively 
modest, with a partial response in one clear cell sarcoma 
patient (2%) and stable disease in 28 patients (60%).51
In a randomized, controlled Phase II study, the combi-
nation of tivantinib with erlotinib, an EGFR TKI, showed 
a trend towards improved progression-free survival (PFS) 
and overall survival (OS) compared with placebo with 
erlotinib; these results were found in a subset of patients 
with non-squamous histology, as well as in patients with 
wild-type EGFR. Interestingly, there was a significant 
benefit in PFS and OS in all 15 patients with mutated 
KRAS. Although the study did not meet its primary end-
point, evidence of activity was demonstrated, particularly 
among patients with KRAS mutations.52 MARQUEE was 
a randomized, double-blind, controlled study evaluating 
tivantinib versus placebo, in combination with erlotinib. 
Patients in the study had locally advanced or metastatic, 
non-squamous NSCLC, and had received prior treatment. 
However, the study was stopped early; at the planned 
interim analysis, there was no improvement in overall 
survival, the primary study endpoint. The combination 
of erlotinib with tivantinib demonstrated a statistically 
significant improvement in PFS, with no safety concerns 
in the intent-to-treat population.53
Two recent preclinical studies have called into question 
the mechanism of tivantinib action. A series of experiments 
demonstrated that the cytotoxic effect of tivantinib on cell 
lines was independent of MET genetic status (wild-type, 
amplified, and/or kinase-deleted).54,55 Both studies observed 
that tivantinib caused G2 arrest, in sharp contrast to other 
MET inhibitors, which cause arrest at the G1 checkpoint. 
Both studies observed alterations in microtubule dynamics; 
in one study, tivantinib was noted to stabilize microtubules, 
while the other report observed that tivantinib destabilized 
microtubules. The potential implications for further clinical 
development of tivantinib as a MET inhibitor are discussed 
in a recent review.56
Multitargeted inhibitors of MET  
and other kinases
Cabozantinib
Cabozantinib is an oral small molecule inhibitor of RET, 
MET, and VEGF-2, with additional activity against VEGF-1, 
VEGF-3, KIT, and FLT-3.57 Eighty-f ive patients with 
advanced solid malignancies, including an expansion cohort 
of 37 patients with medullary thyroid cancer (MTC), were 
enrolled in a Phase I dose-escalation study of oral cabozan-
tinib. The MTD for cabozantinib was 175 mg, and dose-lim-
iting toxicities included palmar-plantar erythrodysesthesia, 
mucositis, aspartate aminotransferase, alanine transaminase, 
and lipase elevations. Ten of 35 evaluable patients with 
MTC had a partial response; an additional 15 patients with 
MTC had stable disease for at least 6 months. Activating 
RET mutations were seen in 81% of patients with MTC and 
the presence of these mutations appeared to correlate with 
response to cabozantinib.58 In a Phase III EXAM study, 
330 patients with locally advanced or metastatic MTC were 
assigned in a 2:1 ratio to receive cabozantinib 160 mg daily 
or placebo, respectively. Median progression-free survival, 
the primary endpoint, was 11.2 months for cabozantinib 
and 4.2 months for placebo (P,0.0001), with an ORR of 
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28% versus 0% for the placebo arm.59 Common grade 3 or 
greater adverse events associated with cabozantinib were 
diarrhea (15.9% versus 1.8%), palmar-plantar erythrodys-
esthesia (12.6% versus 0%), fatigue (9.3% versus 2.8%), 
hypocalcemia (9.3% versus 0%), and hypertension (7.9% 
versus 0%).59
Based on these results, in late 2012 cabozantinib was 
approved by the US Food and Drug Administration (FDA) for 
the treatment of MTC. In the EXAM study, patients with RET 
mutations had a significantly longer median PFS (60 weeks) 
compared to RET mutation-negative patients (25 weeks). 
In the RET mutation-negative subgroup, patients with RAS 
mutations had a median PFS of 47 weeks, accounting for 
most of the benefit observed in this subgroup of patients.59 
Thus, RET and RAS mutations in MTC are predictive of 
response to cabozantinib.
One hundred and seventy one men with castrate refractory 
prostate adenocarcinoma were enrolled in a Phase II random-
ized discontinuation trial with cabozantinib. The patients 
received 100 mg of cabozantinib for a 12-week run-in period, 
followed by randomization of patients with stable disease to 
cabozantinib or placebo. Due to the efficacy of cabozantinib, 
the randomization was halted early. The ORR at 12 weeks, 
a co-primary endpoint, was 5%, while 75% of patients had 
stable disease. In 31 patients with stable disease at 12 weeks 
who were randomly assigned to cabozantinib or placebo, the 
median progression free survival was 23.9 months with cabo-
zantinib and 5.9 months with placebo, resulting in a hazard 
ratio of 0.12. The most common dose limiting toxicities were 
fatigue, hypertension, and hand-foot syndrome.60
Cabozantinib has a black-box warning for gastrointestinal 
perforations (3%), fistula formation (1%), and severe hemor-
rhage, which occurred in 3% of patients in the EXAM trial. 
Additional side effects include venous and arterial throm-
bosis, hypertension, and palmo-plantar erythrodysesthesia. 
Cabozantinib is highly protein-bound (99.7%) and has a 
long half-life of approximately 55 hours. Grapefruit juice 
and other grapefruit products can inhibit CYP enzymes and 
thus should be avoided with cabozantinib. A high-fat meal 
increased cabozantinib C
max
 by 41% and area under curve 
by 57%; patients are thus recommended to not eat from 2 
hours before until 1 hour after cabozantinib use. Concomi-
tant ketoconazole use (a CYP inhibitor) in healthy subjects 
increased single-dose cabozantinib exposure by 38%, while 
rifampin use (a CYP inducer) reduced single-dose cabo-
zantinib exposure by 77%. Thus coadministration of strong 
CYP3A4 inhibitors (ketoconazole, itraconazole, voricon-
azole, clarithromycin, atazanavir, ritonavir) or CYP3A4 
inducers (phenytoin, dexamethasone, carbamazepine, 
rifampin, phenobarbital, St John’s Wort) should be avoided. 
Presently, there is limited data for cabozantinib use in 
hepatic impairment, and it should be avoided in patients 
with moderate to severe impairment. No dose adjustment is 
required for cabozantinib in patients with mild or moderate 
renal insufficiency.61 Cabozantinib is under investigation 
in multiple other tumor types and has shown preliminary 
activity in metastatic breast cancer,62 melanoma,63 hepatocel-
lular carcinoma,64 renal cell carcinoma,65 NSCLC,66 ovarian 
cancer,67 and urothelial carcinoma.68
Crizotinib
Crizotinib is a small molecule inhibitor of the anaplastic 
lymphoma kinase (ALK) with additional activity against 
the MET, ROS, and RON receptors at clinically relevant 
doses. After evaluation of a panel of more than 120 kinases 
in biochemical and phosphorylation assays, crizotinib was 
identified to be nearly 20-fold more selective for both ALK 
and MET than other kinases.69 Based on the results of an 
open-label, two-part Phase I study in 82 patients, crizotinib 
was approved for use in ALK-rearranged advanced NSCLC. 
The overall response rate was 57% (46 partial and one com-
plete response in 82 patients) with crizotinib use in this select 
group of patients with ALK rearrangements.70 Crizotinib was 
also noted to be active in patients with NSCLC with MET 
amplification but no ALK rearrangements and in patients with 
MET-amplified esophagogastric adenocarcinoma.28,71
Anti-HGF monoclonal antibodies
Rilotumumab
Rilotumumab (AMG 102) is a fully human anti-HGF neu-
tralizing immunoglobulin G subclass 2 (IgG2) monoclonal 
antibody. In preclinical tests, a combination of rilotumumab 
and temozolomide, an oral cytotoxic alkylating agent, dis-
played growth inhibitory effects in a human glioblastoma cell 
line U-87 MG. In xenograft models, combining rilotumumab 
with temozolomide or docetaxel (a microtubule inhibitor, 
with cytotoxic activity) induced significant tumor growth 
inhibition compared to either agent alone.72 In Phase I stud-
ies, rilotumumab demonstrated linear kinetics with a mean 
half-life of 18 days. It was well-tolerated at the maximum 
planned dose of 20 mg/kg.73
In the Phase I clinical trial with rilotumumab, 40 patients 
with refractory advanced solid malignancies were enrolled in 
six sequential dose-escalation cohorts and one dose expansion 
cohort. In the dose-escalation cohort, patients were admin-
istered doses of 0.5, 1, 3, 5, 10, or 20 mg/kg every 2 weeks 
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until side-effects or disease progression were observed. Nine 
additional patients received rilotumumab at 20 mg/kg in the 
dose expansion cohort. Rilotumumab was well-tolerated with 
fatigue (13%), anorexia (8%), constipation (8%), and nausea 
(8%) being the most commonly observed toxicities. Sixteen 
of 23 evaluable patients (70%) had stable disease with PFS 
ranging from 7.9 to 40 weeks, with no actual responses.73 A 
Phase Ib study in patients with advanced solid malignancies 
combined rilotumumab with bevacizumab, a humanized 
VEGF-A monoclonal antibody (12 patients), or motesanib, 
a VEGF, PDGFR, and stem cell factor receptor inhibitor 
(2 patients). The patients were sequentially enrolled into four 
cohorts receiving 3, 10, or 20 mg/kg rilotumumab with 10 mg/
kg of bevacizumab, or 3 mg/kg of rilotumumab intravenous 
every 2 weeks with 75 mg of oral daily motesanib. Enrollment 
into the motesanib arm was suspended early due to concern 
over cholecystitis caused by motesanib. Fatigue (72%), nau-
sea (58%), constipation (42%), and peripheral edema (42%) 
were the most common treatment-related side effects. Eight 
of ten patients had reductions in the size of their tumors, with 
four patients demonstrating stable disease at week 24 after 
administration, and PFS ranged from 8–122 weeks.74
A single arm, open-label, two-stage Phase II study enrolled 
61 patients with advanced or metastatic renal cell carcinoma, 
with 40 patients receiving rilotumumab 10 mg/kg every 2 
weeks, and 21 patients receiving the 20 mg/kg dose. The 
median PFS was 3.7 months at 10 mg/kg of rilotumumab and 
2 months at the 20 mg/kg dose; one patient with a confirmed 
partial response remained on maintenance therapy for 2.5 
years. Peripheral edema (46%), fatigue (38%), and nausea 
(28%) were the most common side effects associated with 
rilotumumab.75 In patients with relapsed or recurrent glio-
blastoma, 40 patients received rilotumumab 10 mg/kg every 
2 weeks while 20 patients received rilotumumab at a dose of 
20 mg/kg every 2 weeks as a part of a Phase II clinical trial. 
There were no objective responses based on central assess-
ment, and median OS and PFS were 6.5 months and 4.1 weeks, 
respectively, in the 10 mg/kg dose cohort, and 5.4 months and 
4.3 weeks in the 20 mg/kg dose cohort, respectively. Prior 
bevacizumab treatment had no effect on the study endpoints. 
Fatigue (38%), headache (33%), and peripheral edema (23%) 
were the most common side effects.76
A double-blind Phase II randomized study was performed 
in patients with metastatic castrate-resistant prostate adeno-
carcinoma and who had progressed on prior taxane therapy. 
A total of 144 patients were assigned to receive rilotumumab 
15 mg/kg every 2 weeks, 7.5 mg/kg every 2 weeks, or placebo 
in 1:1:1 manner in combination with mitoxantrone 12 mg/m2 
with prednisone. Median OS was 12.2 months in the com-
bined rilotumumab arms versus 11.1 months in the placebo 
arm, and median PFS was 3 months compared to 2.9 months 
in the placebo arm. The combined rilotumumab arms dem-
onstrated a higher number of patients with peripheral edema 
(24%) compared to the placebo arm (8%).77 A Phase III trial 
(RILOMET-1, NCT01697072)78 of epirubicin, cisplatin, and 
capecitabine (ECX) combined with rilotumumab or placebo 
for untreated, advanced, MET-positive gastric or gastroesoph-
ageal junction (GEJ) adenocarcinoma is currently ongoing.
Ficlatuzumab
Ficlatuzumab (AV-299) is a humanized monoclonal anti-
HGF IgG1 antibody that binds to HGF, thereby inhibiting 
the HGF-MET interaction. In a Phase I study, 24 patients 
with solid malignancies were treated with single agent 
ficlatuzumab at 2, 5, 10, and 20 mg/kg, respectively, every 
2 weeks, while 13 patients received the combination of 
ficlatuzumab 20 mg/kg every 2 weeks and erlotinib 150 mg 
daily. Grade 3 mucositis was seen in one patient on single-
agent ficlatuzumab. Rash and diarrhea were common adverse 
events seen with combination therapy.79 The half-life of 
single-agent ficlatuzumab was observed to be approximately 
15 days, and no MTD was determined. Ficlatuzumab therapy 
was associated with elevated serum HGF levels but no 
changes in serum soluble-MET levels.79
A Phase Ib study combined gefitinib 250 mg daily with two 
dose levels of ficlatuzumab (10 and 20 mg/kg every 2 weeks) 
in Asian patients with unresectable NSCLC. Of the 15 patients 
enrolled in the study, none had dose-limiting toxicities, while 
common adverse events included cough, rash, poor appetite, 
and diarrhea. At the 20 mg/kg dose, five patients had a partial 
response and four had stable disease at 12 weeks of treatment.80 
A multicenter, randomized open-label Phase II study evaluated a 
combination of ficlatuzumab with gefitinib versus gefitinib alone 
in 188 patients of Asian ethnicity with stage IIIB or stage IV 
NSCLC. The overall response rate was comparable for the com-
bination (43%) and the gefitinib alone arms (40%). Median PFS 
was 5.6 months in the ficlatuzumab plus gefitinib arm compared 
to 4.7 months in the gefitinib only arm (P=0.47). The combina-
tion of ficlatuzumab with gefitinib showed a trend for improved 
ORR and PFS in a subgroup of patients with EGFR-sensitizing 
mutations and low MET biomarker levels. Preliminary results 
suggested improved survival with the combination in patients 
with high stromal HGF (P=0.03), but no difference in the overall 
population. Paronychia (47%), acne (27%), peripheral edema 
(38%), and eczema (17%) were the most common side effects 
associated with the combination therapy.81
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TAK701
TAK701 is a humanized anti-HGF monoclonal antibody that 
was found to overcome gefitinib resistance in EGFR-mutated 
human NSCLC cell lines both in vitro and in xenograft 
mouse models.82 A Phase I study with TAK701 in advanced 
solid malignancies revealed no specific dose-limiting toxici-
ties, with cough, fatigue, and constipation as the common 
adverse events.83
Anti-MET monoclonal antibodies
Onartuzumab
Onartuzumab (MetMAb) is a humanized monovalent mono-
clonal antibody which binds to the extracellular SEMA domain 
of MET. As a result, onartuzumab blocks the binding of the 
HGF α-chain to the MET receptor.84 In an orthotopic mouse 
xenograft model with KP4 pancreatic cancer cells, onartu-
zumab inhibited tumor growth, reduced MET phosphorylation 
with a concomitant decrease in Ki-67 index, and improved 
survival of the mice.85 A Phase I dose-escalation study evalu-
ated single agent onartuzumab and a combination of onartu-
zumab plus bevacizumab in advanced solid malignancies in 
43 patients. The half-life for onartuzumab was 11 days, and no 
adverse pharmacokinetic interactions with bevacizumab were 
observed. The most common treatment-related adverse events 
included fatigue, peripheral edema, and hypoalbuminemia. In 
a Phase II study of erlotinib in combination with onartuzumab 
in patients with advanced NSCLC after initial therapy, 69 
patients were randomized to receive onartuzumab 15 mg/kg 
intravenously every 3 weeks in combination with erlotinib 150 
mg daily, and 68 patients received placebo intravenously every 
3 weeks with erlotinib 150 mg daily. In patients with positive 
MET immunohistochemical staining (defined as $50% tumor 
cells with moderate or strong staining intensity by immuno-
histochemistry [IHC]), the addition of onartuzumab to 
erlotinib resulted in a significant improvement in PFS from 
1.5 to 2.9 months and median overall survival from 3.8 to 
12.6 months.86 A Phase III clinical trial evaluating the combi-
nation of erlotinib with onartuzumab in NSCLC (MetLUNG 
study) is currently ongoing.87 A Phase II randomized double-
blind, placebo-controlled clinical trial comparing cytotoxic 
chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin 
(mFOLFOX-6) combined with bevacizumab and placebo to 
mFOLFOX-6 with bevacizumab and onartuzumab is also 
currently ongoing.88
Biomarkers for MeT inhibitors
In the era of targeted agents, it is critically important to 
identify biomarkers which predict response to a specific 
class of agents. Although a number of predictive biomark-
ers to HGF-MET inhibitors are currently being evaluated, 
to date none have yet been validated or FDA-approved. 
Potential biomarkers explored in clinical trials to predict 
response to HGF-MET inhibitors include MET amplification 
(MET/Centromere enumeration probe 7 [CEP7] ratio .2 
in 200 interphase nuclei), MET translocation, MET muta-
tions, quantitative IHC for total MET or phosphorylated 
MET, plasma levels of HGF, and soluble MET receptor. In 
preclinical studies with PHA-665752, a MET inhibitor, the 
investigators demonstrated that MET amplification was an 
excellent predictor of PHA-665752 sensitivity in 41 human 
NSCLC cell lines.89 BAY-853474, another specific MET 
inhibitor, was able to reduce the tumor burden in glioblas-
toma, NSCLC, and gastric cancer xenograft models. The 
inhibition of MET phosphorylation was dose-dependent, 
and the soluble plasma biomarkers HGF, VEGF, and inter-
leukin-8, as well as the MET-ectodomain, could potentially 
be used to monitor the response to treatment.38 However, 
clinical samples showed only moderately elevated levels of 
these biomarkers even with MET amplification.38 This study 
supported the use and development of IHC-based analysis 
of MET phosphorylation in addition to plasma biomarkers 
for monitoring response.
Treatments with ficlatuzumab and rilotumumab have 
been shown to result in an increase in plasma total HGF 
and soluble MET concentrations from baseline. Elevation 
of plasma total HGF and soluble MET concentrations were 
reported as pharmacodynamic biomarkers.76,80 In a Phase Ib/II 
clinical trial combining rilotumumab with panitumumab 
(a human monoclonal antibody to EGFR) for KRAS wild-
type metastatic colorectal carcinomas, response rate to the 
combination correlated with high cytoplasmic staining 
for MET in tumor cells.90 Exploratory biomarker analyses 
performed on patients with advanced NSCLC (n=128) 
receiving onartuzumab in combination with erlotinib dem-
onstrated an OS benefit in MET-positive patients (n=65), 
defined as $50% of tumor cells staining $2+ intensity for 
MET by IHC; HR =0.37, P=0.002). A subgroup analysis 
suggested IHC analysis of MET expression was a more 
sensitive predictor than MET amplification as assessed by 
FISH.91 In a multicenter Phase II randomized controlled trial, 
MET-expression-positive patients (defined as MET $2+ in 
.50% of tumor at IHC) with unresectable hepatocellular 
carcinoma showed a significant benefit with tivantinib in the 
second-line setting.92 Interestingly, another Phase II trial with 
tivantinib demonstrated no obvious relationship of treatment 
outcome with biomarkers, including MET gene amplification, 
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phospho-MET and HGF expression in tumor, and serum 
HGF.93 Recently, the use of gene expression profiling has 
allowed for the identification of specific gene signatures 
which can be used to classify and predict tumor responses 
to targeted agents or chemotherapy. Such signatures are cur-
rently being developed and tested for colorectal carcinomas.94 
Thus, future clinical trials need to better identify and refine 
biomarkers, which will allow for better prediction of response 
to MET inhibitors.
Mechanisms of resistance  
to HGF-MeT inhibitors
Since solid malignancies are comprised of highly 
 hetero geneous groups of cells, the use of targeted inhibitors may 
select a malignant clone of cells, which are inherently resistant 
to blockage of the HGF-MET pathway. Acquired resistance in 
cancer cells can develop by point mutations, which inhibit the 
interaction and/or binding of a molecule to its target receptor. 
Another mechanism of acquired resistance is activation of 
compensatory signaling pathways or mechanisms, which can 
bypass the effects of targeted agents. In a preclinical model, 
exposure to MET inhibitors PHA-665752 and PF-2341066 led 
to MET resistance through an acquired mutation in the MET 
activation loop (Y1230H/C).95 In addition, overexpression of 
TGF-α, a ligand for EGFR, resulted in activation of the EGFR 
pathway and subsequent resistance to MET inhibitors.95 In 
a MET-amplified gastric cancer cell line GTL16, prolonged 
exposure to PF-04217903 resulted in 7q32-34 amplification and 
overexpression of a novel Staphylococcal Nuclease And Tudor 
Domain Containing 1-v-raf murine sarcoma viral oncogene 
homolog B (SND1-BRAF) fusion protein. The constitutively 
active SND1-BRAF fusion protein resulted in upregulation 
and activation of the mitogen-activated protein kinase pathway, 
which conferred resistance to MET inhibition.96 After prolonged 
exposure to small molecule MET inhibitors, resistant cells devel-
oped MET and KRAS amplification. KRAS amplification was 
associated with loss of MET dependence and resistance to MET 
inhibitors.96 A patient with MET-mutated papillary renal cell car-
cinoma treated with PF-04217903 was noted to have an acquired 
tandem duplication of the mutated MET gene and developed 
resistance to PF-04217903- mediated MET inhibition.97 Strate-
gies to overcome HGF-MET resistance would involve targeting 
of multiple compensatory pathways simultaneously either by 
using multitargeted agents such as cabozantinib (MET, VEGF), 
crizotinib (MET, ALK), or by combining targeted agents like 
onartuzumab or ficlatuzumab with erlotinib/ gefitinib (MET/
HGF and EGFR inhibitors respectively). The use of inhibitors of 
heat shock protein 90 (HSP90), a molecular chaperone to MET, 
and a wide range of other key cellular proteins may offer another 
approach to overcome resistance to MET inhibition.89,98
Summary
The HGF-MET axis is frequently dysregulated in cancer, 
 especially in advanced or metastatic disease.  Upregulation of 
the HGF-MET axis can promote resistance to small molecule 
inhibition of several important cellular signaling pathways, 
including the EGFR, RAS-RAF-MEK, and Akt-mTOR 
 pathways. A number of potential predictive biomarkers includ-
ing MET amplification (MET/CEP7 ratio .2 in 200 interphase 
nuclei), MET translocation, MET mutation analysis, quantitative 
IHC for total MET and phosphorylated MET, plasma levels of 
HGF, and soluble MET receptor, are currently being evaluated 
in clinical studies. HGF-MET inhibitors hold promise as novel 
molecules that can be used either as monotherapy or as part of 
combination therapy with EGFR, RAS-RAF-MEK, and Akt-
mTOR inhibitors in the treatment of various human cancers. 
To conclude, in the era of personalized medicine, there is an 
increased need to validate biomarkers in specific tumor types to 
identify patients who will benefit from HGF-MET inhibitors.
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